Anti-CD33 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Drug Profile

Anti-CD33 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer University of Texas M. D. Anderson Cancer Center; ZIOPHARM Oncology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 02 May 2017 The US FDA accepts an IND application for Acute myeloid leukaemia in USA
  • 12 Jul 2016 ZIOPHARM in collaboration with the University of Texas M. D. Anderson Cancer Center plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA (NCT03126864)
  • 01 Mar 2016 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top